Brent Hatzis-Schoch bought BDTX once, on Feb 3, 2020

Brent Hatzis-Schoch is a corporate executive and attorney serving as Chief Operating Officer and General Counsel of Black Diamond Therapeutics, Inc., a biotechnology company focused on precision medicines for cancer.( With more than 20 years of experience in the global pharmaceutical and biotechnology industry, he has held senior leadership roles spanning legal, compliance, operations, and corporate governance at both commercial-stage and development-stage life sciences companies.( Prior to joining Black Diamond in 2019, he was Senior Vice President, General Counsel and Corporate Secretary at Radius Health, Inc., where he oversaw legal, intellectual property, contracts management, compliance, regulatory, and quality assurance functions and helped guide the company’s evolution from a development-stage enterprise to a commercial organization.(

Earlier in his career, Hatzis-Schoch served as Senior Vice President and Chief Legal Counsel at Merz Pharma in Frankfurt, Germany, with global responsibility for legal, IP, and compliance, and held General Counsel roles at publicly traded German biopharmaceutical companies Agennix AG and GPC Biotech.( He previously worked as European legal counsel for Baxter International and Associate General Counsel at Pharmacia, building his expertise in cross-border pharmaceutical and biotech regulation and corporate law.( Hatzis-Schoch began his legal career in private practice and holds a Juris Doctor from The George Washington University Law School, where he studied from 1987 to 1990, and a B.A. in International Relations from the University of Delaware; he was also a Fulbright Scholar at the University of Cologne in Germany.(

Written by Perplexity from public sources.